Isotechnika Pharma Inc IPHAF

RE: Sell side

[teevee]

Paladin owns the rights to the molecules, all licensing and retains a royalty on all commercialization. As for the stock, Paladin has a double and will no doubt continue to sell. It is all about monetizing this asset. Did you not notice how much cash ISA had to pay Paladin to modify their licensing agreement with Paladin? My advise is to take delivery of your iSA share cert, frame it, hang in bathroom with a sign below: "In case of emergency, break glass";-)